Airway Therapeutics Closes $15.5 Million Series C Financing to Advance Preclinical and Clinical Research and Development Programs to Prevent and Treat Serious Respiratory Diseases
Retrieved on:
Wednesday, January 8, 2020
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious diseases, Baby, Maternity, Consumer, Medical specialties, Neonatology, RTT, Childhood, Respiratory diseases, Bronchopulmonary dysplasia, Infancy, Human orthopneumovirus, Cystic fibrosis, Preterm birth, Respiratory disease, Lung, AT-100, bronchopulmonary dysplasia, Airway Therapeutics
This funding will enable clinical development of AT-100 (rhSP-D), an investigational preventive treatment for the serious respiratory disease bronchopulmonary dysplasia (BPD) in very preterm infants, while also supporting preclinical research in influenza, respiratory syncytial virus (RSV) and cystic fibrosis.
Key Points:
- This funding will enable clinical development of AT-100 (rhSP-D), an investigational preventive treatment for the serious respiratory disease bronchopulmonary dysplasia (BPD) in very preterm infants, while also supporting preclinical research in influenza, respiratory syncytial virus (RSV) and cystic fibrosis.
- Preclinical research in BPD demonstrated that Airways AT-100 prevented the onset of lung tissue damage, and reduced inflammation and infection triggered by mechanical ventilation and oxygen support.
- Funding from the Series C financing will enable Airway to further develop its preclinical package for influenza, RSV and cystic fibrosis in preparation for additional clinical trials in 2021.
- Mr. Patel has more than 25 years of experience covering all aspects of biopharmaceutical clinical development, including program management, clinical operations, regulatory affairs, analytical development and quality.